ArticleThe Lancet regional health. Western Pacific2026
Antimicrobial resistance and treatment mismatch in culture-proven sepsis among very preterm infants in Chinese NICUs: a cohort study.
Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Plasma transfusion in neonatal sepsis.World journal of pediatrics : WJP · 2026Article
- Antimicrobial Stewardship Program in a Low-Middle Income Country: Impact of an Antibiotic Guideline for Neonatal Early-Onset Sepsis.Antibiotics (Basel, Switzerland) · 2026Article
- Trends in pathogens and antimicrobial resistance in culture-proven neonatal sepsis over a decade (2015-2024): the impact of COVID-19 pandemic.Frontiers in cellular and infection microbiology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The real-world effectiveness of guideline-recommended antibiotics for neonatal sepsis remains uncertain in settings with high antimicrobial resistance. Evidence derived from large-scale, contemporary data that integrates pathogens, resistance, and treatment is needed. This study aims to assess the epidemiology, antimicrobial resistance, and antibiotic treatment practices for sepsis among very preterm infants (VPIs) in China. Methods: We analysed prospectively collected data from all VPIs admitted to 88 tertiary neonatal intensive care units (NICUs) in the Chinese Neonatal Network between 2019 and 2022. Findings: Among 38,560 VPIs, 1.1% (95% CI 1.0-1.2) developed early-onset sepsis (EOS; case-fatality 24.0%, 95% CI 19.8-28.8), and 5.8% (95% CI 5.6-6.1) developed late-onset sepsis (LOS; case-fatality 12.2%, 95% CI 10.9-13.7). Gram-negative bacteria predominated in both EOS (59.0%) and LOS (48.3%), with resistance to cefotaxime and ceftazidime reaching 69.8% and 28.6% in EOS, and even higher rates in LOS. An ampicillin plus ceftazidime regimen would fail to cover 13.3% of EOS cases, while gentamicin-based regimens showed comparable coverage. Nearly all Gram-positive EOS pathogens were susceptible to penicillin/ampicillin, yet 16.6% of definitive therapy involved vancomycin or linezolid. Broad-spectrum antibiotics were frequently continued after pathogen identification in both EOS and LOS, with insufficient de-escalation. Interpretation: Sepsis remains a major burden among VPIs in China, with Gram-negative bacteria exhibiting alarming resistance and mismatches between guideline-recommended regimens and real-world effectiveness. These findings highlight the need to integrate susceptibility and prescribing data to inform national guideline updates and targeted antimicrobial stewardship strategies. Funding: This work was funded by China Medical Board (grant #20-370).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.